Kyverna Therapeutics Files 10-Q Post-IPO
Ticker: KYTX · Form: 10-Q · Filed: May 13, 2025 · CIK: 1994702
Sentiment: neutral
Topics: 10-Q, IPO, biotech, R&D
Related Tickers: KYTX
TL;DR
Kyverna (KYTX) filed its Q1 10-Q, showing R&D spend and confirming post-IPO status.
AI Summary
Kyverna Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of 2024. Notably, Kyverna Therapeutics completed its Initial Public Offering (IPO) on March 27, 2025.
Why It Matters
This filing provides investors with an update on Kyverna Therapeutics' financial performance and operational status following its recent IPO, offering insights into its R&D investments.
Risk Assessment
Risk Level: medium — As a biotechnology company with recent IPO activity, Kyverna Therapeutics faces inherent risks related to clinical trial success, regulatory approvals, and market adoption of its therapies.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the period covered by the 10-Q filing.)
- 2025-03-27 — IPO Date (Marks the completion of the company's Initial Public Offering.)
- 2024-01-01 to 2024-03-31 — R&D Expense Period (Specifies the timeframe for which Research and Development expenses are reported.)
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of reporting period
- 2024-01-01 (date) — Start of R&D expense reporting period
- 2024-03-31 (date) — End of R&D expense reporting period
- 2025-03-27 (date) — Date of IPO
- Kite Pharma, Inc. (company) — Mentioned in relation to a license agreement
FAQ
What were Kyverna Therapeutics' research and development expenses for the first quarter of 2024?
The filing indicates reporting for 'us-gaap:ResearchAndDevelopmentExpenseMember' for the period of 2024-01-01 to 2024-03-31, though specific dollar amounts are not detailed in this excerpt.
When did Kyverna Therapeutics complete its Initial Public Offering (IPO)?
Kyverna Therapeutics completed its IPO on March 27, 2025.
What is the primary business of Kyverna Therapeutics?
Kyverna Therapeutics is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
What is the fiscal year end for Kyverna Therapeutics?
Kyverna Therapeutics' fiscal year ends on December 31.
Does the filing mention any significant agreements or partnerships?
Yes, the filing mentions a 'Kite License Agreement' with 'Kite Pharma, Inc.'
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Kyverna Therapeutics, Inc. (KYTX).